Chinook Therapeutics Inc. (KDNY)
$40.39
$0.00 (0.00%)As on 18-Aug-2023 09:30EDT
Market cap
$2,708 Mln
Revenue (TTM)
$6 Mln
P/E Ratio
--
P/B Ratio
3.1
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-116 Mln
-
ROE
-0.6 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-11.5
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-3.5
-
Face value
--
-
Shares outstanding
67,049,500
8 Years Aggregate
CFO
$-378.54 Mln
EBITDA
$-294.80 Mln
Net Profit
$-731.97 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Chinook Therapeutics (KDNY)
| 54.2 | 2.6 | 87.8 | 86.9 | 46.7 | 7.0 | -- |
|
BSE Sensex*
| -9.6 | -2.7 | 2.9 | -5.0 | 5.4 | 5.7 | 10.4 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|---|---|---|---|---|---|---|---|
|
Chinook Therapeutics (KDNY)
| 60.6 | 2.8 | 168.8 | -55.3 | -64.6 | -34.2 | -59.5 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Chinook Therapeutics (KDNY)
|
40.4 | 2,708.1 | 5.9 | -243.2 | -4,288.1 | -60.9 | -- | 3.1 |
| 86.3 | 12,161.6 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.2 | |
| 72.7 | 10,109.8 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.5 | |
| 59.0 | 14,621.6 | 2,435.9 | 860.6 | 31.0 | 43 | 18.6 | 7.9 | |
| 110.2 | 12,506.3 | 1,663.7 | 413.6 | 36.3 | 430 | 32.3 | 86.7 | |
| 358.2 | 10,603.5 | 440.5 | 241.5 | 33.4 | 18.7 | 44.9 | 8.1 | |
| 117.4 | 9,761.1 | 105.0 | -299.7 | -227.2 | -19.4 | -- | 6.5 | |
| 541.1 | 12,501.2 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 23.9 | |
| 591.3 | 16,503.9 | 2,782.3 | 491.5 | 21.1 | 110.1 | 34.7 | 38.2 | |
| 124.0 | 9,808.7 | 0.0 | -450.1 | -- | -44.6 | -- | 8.4 |
Shareholding Pattern
View DetailsAbout Chinook Therapeutics (KDNY)
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin... receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington. As of August 11, 2023, Chinook Therapeutics, Inc. operates as a subsidiary of Novartis AG. Read more
-
Pres, CEO & Director
Mr. Eric L. Dobmeier J.D.
-
Pres, CEO & Director
Mr. Eric L. Dobmeier J.D.
-
Headquarters
Seattle, WA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Chinook Therapeutics (KDNY)
What is the current share price of Chinook Therapeutics Inc (KDNY) Today?
The share price of Chinook Therapeutics Inc (KDNY) is $40.39 (NASDAQ) as of 18-Aug-2023 09:30 EDT. Chinook Therapeutics Inc (KDNY) has given a return of 46.67% in the last 3 years.
What is the current PB & PE ratio of Chinook Therapeutics Inc (KDNY)?
Since, TTM earnings of Chinook Therapeutics Inc (KDNY) is negative, P/E ratio is not available.
The P/B ratio of Chinook Therapeutics Inc (KDNY) is 3.06 times as on 18-Aug-2023, a 43 discount to its peers’ median range of 5.33 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2022 |
-9.82 |
4.10 |
2021 |
-8.64 |
1.93 |
2020 |
-8.22 |
2.00 |
2019 |
-0.81 |
-0.92 |
2018 |
-0.88 |
0.62 |
What is the 52 Week High and Low of Chinook Therapeutics Inc (KDNY)?
The 52-week high and low of Chinook Therapeutics Inc (KDNY) are Rs -- and Rs -- as of 07-Sep-2026.
What is the market cap of Chinook Therapeutics Inc (KDNY)?
Chinook Therapeutics Inc (KDNY) has a market capitalisation of $ 2,708 Mln as on 18-Aug-2023. As per SEBI classification, it is a company.
Should I invest in Chinook Therapeutics Inc (KDNY)?
Before investing in Chinook Therapeutics Inc (KDNY), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.